20:04 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

China approves Linzess for IBS-C

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said China's National Medical Products Administration approved Linzess linaclotide to treat irritable bowel syndrome with constipation (IBS-C). The company expects to launch the guanylate cyclase C (GCC; GUCY2C) agonist in China...
00:53 , Jan 18, 2019 |  BC Week In Review  |  Company News

Tribe, Allergan appeal sovereign immunity patent case to Supreme Court

The Saint Regis Mohawk Tribe and Allergan plc (NYSE:AGN) asked the U.S. Supreme Court to review a federal court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review...
23:11 , Jan 15, 2019 |  BC Extra  |  Company News

Tribe, Allergan appeal sovereign immunity patent case to Supreme Court

The Saint Regis Mohawk Tribe and Allergan plc (NYSE:AGN) asked the U.S. Supreme Court to review a federal court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review...
01:06 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection; graft rejection Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:55 , Jan 2, 2019 |  BC Extra  |  Politics & Policy

Part D beneficiaries hit hardest under 2019 price hikes

Drug price increases announced beginning Jan. 1 will disproportionately affect Medicare Part D beneficiaries, reinforcing a practice the Trump administration has sought to curb. Data from Evercore ISI Research on 13 pharmaceutical and biotech companies...
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
19:55 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Dec. 18 with an untranched $42 million series A round and a basket of discovery programs targeting undisclosed cancer drivers. The financing was co-led by founding investors...
13:02 , Dec 18, 2018 |  BC Extra  |  Financial News

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Tuesday with an untranched $42 million series A round and a basket of discovery programs targeting undisclosed cancer drivers. The financing was co-led by founding investors City...